The sources Helixera watches first.

Current FDA Structured Product Label records and label version metadata.

Official U.S. National Library of Medicine label repository.

Official recall and enforcement reports matched to tracked therapies.

Official FDA enforcement dataset exposed through openFDA.

Public regulatory announcements, approvals, safety communications, labels, and meeting materials.

Primary U.S. regulatory source for drug, biologic, and safety information; essential for regulatory movement and approval-context signals.

FDA public datasets and APIs for labels, adverse events, recalls, and related regulatory data.

Machine-readable FDA data source that supports repeatable ingestion and source-linked regulatory monitoring.

European regulatory opinions, medicine assessments, safety updates, and committee materials.

Primary European regulatory source that complements FDA tracking for globally relevant treatment and safety movement.

Recent official filings for publicly traded companies tracked by disease.

The SEC is the primary source for public-company filings.

Biotech company news, financing, partnerships, pipeline updates, and industry movement.

Founder-approved trusted publication for biotech and life-science company signals relevant to disease intelligence.

Official company newsroom URLs awaiting per-feed verification.

First-party company communications are useful when clearly labeled and checked against primary records.

Biotech business, pipeline, deal, and financing coverage.

Useful secondary publication for spotting company movement and biotech-market context.

Indexed biomedical literature across Helixera launch diseases.

Primary public literature index operated by the National Library of Medicine; used to identify papers, reviews, publication dates, and source abstracts.

DOI registration metadata and publication relationships for disease-relevant scholarly records.

Crossref is the primary open DOI metadata registry and is used for identifier resolution rather than clinical interpretation.

Biomedical abstracts, identifiers, citations, MeSH metadata, and lawful open-access availability.

Europe PMC is an official EMBL-EBI life-science literature service with a documented REST API.

Official NIH research project, investigator, institution, funding, and project-date metadata.

NIH RePORTER is the official public database for NIH-funded projects and durable grant identifiers.

Disease-relevant biology preprints and server-reported links to later journal publication.

Official bioRxiv API with explicit version, license, category, DOI, and publication-match metadata.

Preprint research before peer review.

Preprints can surface early research signals before formal publication, but must be labeled clearly and treated as provisional.

Disease-relevant health-science preprints and server-reported links to later journal publication.

Official medRxiv API with explicit version, license, category, DOI, and publication-match metadata.

Peer-reviewed research and review coverage across biomedical fields.

Trusted scientific publisher useful for high-signal papers, reviews, and disease-field context.

Peer-reviewed clinical research, reviews, and clinical-trial publications.

High-trust medical journal for major clinical studies and disease-relevant evidence.

Neurology-focused peer-reviewed research, reviews, and disease-field context.

High-trust neurology journal relevant to Helixera neurodegenerative and rare neurological launch diseases.

Peer-reviewed biomedical and translational research across disease areas.

Trusted scientific publisher for mechanistic, translational, and disease-biology signals.

Peer-reviewed clinical research, reviews, and medical commentary.

Trusted medical journal network for clinical and health-system context.

Trial registrations, recruiting status, study changes, sponsors, and trial locations.

Primary U.S. public registry for clinical trials; useful for tracking new studies, status changes, phase, enrollment, and sponsor movement.

Federal research and disease-context updates for neurological and rare neurological conditions.

Primary government source for research context, disease education, funding, and expert-level public summaries.

ALS community, patient-led advocacy, policy movement, and disease-community signals.

Founder-approved trusted ALS source for patient-led community signals and advocacy context.